Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGT1 | P19440 | 1/20 | 0.34 |
| ▸ | ARG1 | P05089 | 1/20 | 0.32 |
| ▸ | ARG2 | P78540 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6378582 | 1.00 | GGT1 (0.34) | GGT1ARG1ARG2 | |
| SCHEMBL6378587 | 1.00 | GGT1 (0.34) | GGT1ARG1ARG2 | |
| SCHEMBL5845322 | 1.00 | GGT1 (0.34) | GGT1ARG1ARG2 | |
| SCHEMBL5830041 | 0.85 | GGT1 (0.39) | GGT1ARG1ARG2 | |
| SCHEMBL6059928 | 0.85 | GGT1 (0.39) | GGT1ARG1ARG2 | |
| SCHEMBL6193056 | 0.85 | GGT1 (0.39) | GGT1ARG1ARG2 | |
| SCHEMBL6192147 | 0.85 | GGT1 (0.39) | GGT1ARG1ARG2 | |
| SCHEMBL5830037 | 0.85 | GGT1 (0.39) | GGT1ARG1ARG2 | |
| SCHEMBL6192143 | 0.85 | GGT1 (0.39) | GGT1ARG1ARG2 | |
| SCHEMBL6059925 | 0.85 | GGT1 (0.39) | GGT1ARG1ARG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7005450-B2 | 2-amino-2-alkyl-4 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors | PHARMACIA CORPORATION (US) | 2006-02-28 | — | — | US | claimed |
| US-20040192779-A1 | 2-amino-2-alkyl-4 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors | DURLEY RICHARD C (US) | 2004-09-30 | — | — | US | claimed |
| EP-1317416-A2 | 2-AMINO-2-ALKYL-4 HEXENOIC AND HEXYNOIC ACID DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | Pharmacia Corporation (US) | 2003-06-11 | — | — | EP | claimed |
| US-20020128510-A1 | 2-Amino-2-alkyl-4 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors | PHARMACIA CORPORATION | 2002-09-12 | — | — | US | claimed |
| WO-2002022559-A2 | 2-AMINO-2-ALKYL-4 HEXENOIC AND HEXYNOIC ACID DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | PHARMACIA CORPORATION (US) | 2002-03-21 | — | — | WO | claimed |
| US-7005450-B2 | 2-amino-2-alkyl-4 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors | PHARMACIA CORPORATION (US) | 2006-02-28 | — | — | US | disclosed |
| US-20040192779-A1 | 2-amino-2-alkyl-4 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors | DURLEY RICHARD C (US) | 2004-09-30 | — | — | US | disclosed |
| US-20020128510-A1 | 2-Amino-2-alkyl-4 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors | PHARMACIA CORPORATION | 2002-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192779-A1 | 2-amino-2-alkyl-4 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors | ALOX12, ALOX5, ALOX15 | GGT1 879/4885ARG1 200/4885ARG2 110/4885 |
| US-20020128510-A1 | 2-Amino-2-alkyl-4 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors | ALOX12, ALOX5, ALOX15 | GGT1 879/4885ARG1 200/4885ARG2 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.